Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Cognitive Dysfunction 1Central Nervous System Neoplasms 1Brain Neoplasms 1

Interventions

Temozolomide 30Radiotherapy 23Filgrastim 12Carmustine 12Irinotecan 11Carboplatin 11Chemotherapy, Adjuvant 9O(6)-benzylguanine 8Etoposide 7Surgical Procedures, Operative 6Magnetic Resonance Spectroscopy 6Vincristine 5Peripheral Blood Stem Cell Transplantation 5Granulocyte Colony-Stimulating Factor 5Cyclophosphamide 5sargramostim 4motexafin gadolinium 4Topotecan 4Thiotepa 4Paclitaxel 4Melphalan 4Gene Expression Profiling 4Gemcitabine 4Drug Therapy 4Busulfan 4temsirolimus 3etoposide phosphate 3Specimen Handling 3Mass Spectrometry 3Imatinib Mesylate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Central Nervous System Neoplasms × Donepezil × Clear all
NCT00594633 2016-01-14

Adjunctive Donepezil Therapy and Genetic Risk Factors of Cognitive Dysfunction in Brain Tumor Survivors

Memorial Sloan Kettering Cancer Center

Phase 1 Completed
25 enrolled
CNS

Brain Neoplasms, Central Nervous System Neoplasms, Cognitive Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon âš¡